Biotechnology Law Report

Papers
(The median citation count of Biotechnology Law Report is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Continuing CRISPR Patent Disputes May Be Usurped by Its Potential Role in Fighting Global Pandemics9
Selected Developments in Biotechnology Law and the Biotechnology Industry3
Regulation of Artificial Intelligence in Drug Discovery and Health Care3
Selected Developments in Biotechnology Law and the Biotechnology Industry3
In Juno v. Kite the Federal Circuit Strikes Down Patent Directed Towards Pioneering Innovation in CAR T-Cell Therapy3
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines2
UK Biotech Corporate Finance Trends Post COVID-192
GlaxoSmithKline v. Teva: Holding a Generic Liable for an Artificial Act of Inducement2
Legal and Ethical Challenges in the Construction of China's Biobanks2
Legitimacy of Experimental Use of Patented Research Tools by Chinese Universities2
Exclusions from Patentability with an Emphasis on Biotechnological Inventions: A Comparative Study1
Idorsia Pharmaceuticals, Ltd. v. Iancu United States Court of Appeals of the Federal Circuit, 2020 811 Fed. Appx. 650 (nonprecedential)1
Arbitrability of Disputes Arising from Patents: A Comparative Study1
State Universities Push the Limits of Eleventh Amendment Sovereign Immunity at the Federal Circuit1
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR1
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 13711
Par Pharm., Inc. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1273, 2020 WL 6846347 (Non-precedential)1
Myco Indus., Inc. v. BlephEx, LLC United States Court of Appeals of the Federal Circuit, 2020 955 F.3d 11
United Therapeutics Corp. v. Liquidia Techs., Inc.1
Genentech, Inc. v. Immunex Rhode Island Corp. United States Court of Appeals of the Federal Circuit, 2020 964 F.3d 11091
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Hospira, Inc. v. Fresenius Kabi USA, LLC United States Court of Appeals of the Federal Circuit, 2020 946 F.3d 13221
In re Huping Hu United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2104, 2021 WL 1016437 (non-precedential)1
Observation on the Admission Situation of the Anti-Coronavirus Drug “Remdesivir” in China1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Sanofi-Aventis Deutschland GmbH v. Mylan Pharms. Inc.1
Introduction on Biosafety Law of the People's Republic of China and Linkage Thereof with International and Domestic Regulations1
Par Pharm., Inc. v. Eagle Pharms., Inc.1
Legislative Moves on Biosecurity in China1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Novartis Pharms. Corp. v. Accord Healthcare, Inc.1
AstraZeneca AB v. Mylan Pharms. Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Horizon Pharma, Inc. v. Dr. Reddy's Labs. Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-1607, 2021 WL 48428 (Non-precedential)1
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich1
Amgen Inc. v. Sanofi, Aventisub LLC United States Court of Appeals of the Federal Circuit, 2021 987 F.3d 10801
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Dana-Farber Cancer Inst., Inc. v. Ono Pharm. Co. United States Court of Appeals of the Federal Circuit, 2020 964 F.3d 13651
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Incorrect Translation Causing a Claim to Be Indefinite Under 35 U.S.C. § 112—A Case Study of IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Eagle Pharm. Inc. v. Slayback Pharma LLC United States Court of Appeals of the Federal Circuit, 2020 958 F.3d 11711
Bayer Healthcare LLC v. Baxalta Inc. United States Court of Appeals of the Federal Circuit, 2021 989 F.3d 9641
Biogen Int'l GmbH v. Banner Life Scis. LLC United States Court of Appeals of the Federal Circuit, 2020 956 F.3d 13511
SawStop Holding LLC v. Vidal United States Court of Appeals of the Federal Circuit, 2022 48 F.4th 13551
A Review of Patent Regimes on Health Biotechnology Innovation in India1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I1
Juno Therapeutics, Inc. v. Kite Pharma, Inc. United States Court of Appeals of the Federal Circuit, 202110 F.4th 13301
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC1
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine1
Univ. of Massachusetts v. L'Oreal S.A.1
Bio-Rad Labs., Inc. v. 10X Genomics Inc. United States Court of Appeals of the Federal Circuit, 2020 967 F.3d 13531
Valeant Pharm. Int'l, Inc. v. Mylan Pharm. Inc. United States Court of Appeals of the Federal Circuit, 2020 955 F.3d 251
Genentech, Inc. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2020 946 F.3d 13331
Hologic, Inc. v. Minerva Surgical, Inc. United States Court of Appeals of the Federal Circuit, 2020 957 F.3d 12561
The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods1
Biogen MA Inc. v. EMD Serono, Inc. United States Court of Appeals of the Federal Circuit, 2020 976 F.3d 13261
Verinata Health, Inc. v. Ariosa Diagnostics, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2018-2198, 2020 WL 1970571 (Nonprecedential)1
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies1
XY, LLC v. Trans Ova Genetics, LC United States Court of Appeals of the Federal Circuit, 2020 968 F.3d 13231
Vectura Ltd. v. Glaxosmithkline LLC. United States Court of Appeals of the Federal Circuit, 2020 981 F.3d 10301
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control1
Ferring B.V. v. Allergan, Inc. United States Court of Appeals of the Federal Circuit, 2020 980 F.3d 8411
14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China1
Eli Lilly & Co. v. Apotex, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1328, 2020 WL 7490251 (Non-precedential)1
Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC United States Court of Appeals of the Federal Circuit, 2023 No. 2023-1186, 2023 WL 21986400
How a Dosage Regimen Patent for RRMS Treatment May Satisfy the Written Description Requirement—A Lesson from Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc.0
Regulation of Clinical Trials and Pandemic Research: Upholding Ethical Standards During a COVID-19 Crisis0
Trustees of Columbia Univ. in City of New York v. Illumina, Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2302, 2021 WL 317661 (nonprecedential)0
ChromaDex, Inc. v. Elysium Health, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 12800
The Compulsory Licensing for Exploiting Patented COVID-19 Pharmaceutical Treatment: Legal Approaches of Some Arab Countries0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
In re Bd. of Trustees of Leland Stanford Junior Univ. United States Court of Appeals of the Federal Circuit, 2021 No. 2020-1012, 2021 WL 9227270
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Pharmaceutical Patent Term Compensation System in China—Centered on Article 42(3) of the Amendment to the Patent Law of the People's Republic of China0
Gensetix, Inc. v. Bd. of Regents of Univ. of Texas Sys. United States Court of Appeals of the Federal Circuit, 2020 966 F.3d 13160
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Gilead Scis., Inc. v. United States0
Illumina, Inc. v. Ariosa Diagnostics, Inc. United States Court of Appeals of the Federal Circuit, 2020 952 F.3d 13670
Argentum Pharm. LLC v. Novartis Pharm. Corp. United States Court of Appeals of the Federal Circuit, 2020 956 F.3d 13740
Cornell Rsch. Found., Inc. v. Vidal0
China Releases Document on Ethics Review of Life Sciences: Comments and Compliance Guidelines0
GlaxoSmithKline II and Other Recent Developments in Induced and Contributory Patent Infringement0
Reflections on the Pharmaceutical Patent Protection in China0
Taiwan's Efforts to Recreate Remdesivir0
Regulation of Biomedical Research: Global and Indian Perspective0
ModernaTx, Inc. v. Arbutus Biopharma Corp.0
AI (Re)Defining Pharmaceutical Exclusivities0
Correction to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sr0
Dilemma and Solution of Intellectual Property Protection of Biological Genetic Resources0
Divya Pharmacy v. Union of India High Court of Uttarakhand, India; 2018 SCC Online Utt. 10350
Bio-Rad Lab'ys, Inc. v. Int'l Trade Comm'n0
The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words)0
The EPO Guidelines They Are a-Changin’0
Amgen Inc. v. Sandoz Inc. United States Court of Appeals of the Federal Circuit, 2023 No. 2022-1147, 2023 WL 29941660
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Medytox, Inc. v. Galderma S.A.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
A 2023 Review of Legislation Aimed at Increasing Generic and Biosimilar Competition0
Unproven Stem Cell Industry in the U.S.: Regulatory Challenges and Enforcement Issues0
Eagle Pharm., Inc. v. Azar United States Court of Appeals of the District of Columbia, 2020 952 F.3d 3230
Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China0
Recent Developments at the Intersection of Pharma, Patents, and Antitrust Law0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
UCB, Inc. v. Actavis Lab'ys UT, Inc.0
Amendment of China's Biotechnology Laws in Relation to the Prevention and Containment of the COVID-19 Pandemic0
Research on Intellectual Property Right Protection of Genetic Resources in China Under Benefit-Sharing0
Persion Pharm. LLC v. Alvogen Malta Operations Ltd. United States Court of Appeals of the Federal Circuit, 2019 945 F.3d 11840
Reconsidering Conflicts over Gene Patents in View of Taiwan Patent Law0
Research on the Latest Progress of “Mechanism for Early Resolution of Patent Disputes” for Biological Products in China0
Supplementary Protection Certificates in Europe: Clarity at Last?0
Minerva Surgical, Inc. v. Hologic, Inc.0
Review of the UK's R&D Tax Reliefs—A Good News Story for the UK's Life Sciences Sector?0
Japanese CRISPR Patent and Biotech Developments in the Early Reiwa Era0
Trustees of Columbia Univ. in City of New York v. Illumina, Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2302, 2021 WL 317661 (nonprecedential)0
The Fate of FTC v. Actavis, Inc. in the Biosimilar Context—Does and Should the FTC v. Actavis Decision Apply to Reverse Patent Settlements Between Brand Drug and Biosimilar Manufacturers0
To What Extent Does Mayo v. Prometheus Allow for the Patenting of Diagnostic Methods?0
The Drawing-Up of Laws on Research Involving Human Embryos in Australia: Lack of an Islamic Voice0
Patentability Analysis of “Intelligent” Disease Diagnosis Methods in China in the Era of Smart Health Care0
Actelion Pharms. LTD v. Mylan Pharms. Inc.0
BASF Corp. v. SNF Holding Co. United States Court of Appeals of the Federal Circuit, 2020 955 F.3d 9580
Trade Secret Protection on a Publicly Sold, Patented Spinal Implant Device: Life Spine, Inc. v. Aegis Spine, Inc.0
Landscape of Genome Editing Technology Patents in the European Patent Office with a Focus on CRISPR-Related Opposition Proceedings0
Immunex Corp. v. Sandoz Inc. United States Court of Appeals of the Federal Circuit, 2020 964 F.3d 10490
Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp. United States Court of Appeals of the Federal Circuit, 2022 50 F.4th 1470
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Takeda Pharm. Co. Ltd. v. Torrent Pharm. Ltd. United States Court of Appeals of the Federal Circuit, 2021 No. 2020-1552, 2021 WL 560763 (nonprecedential)0
Bracco Diagnostics Inc. v. Maia Pharm., Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1387, 2020 WL 7393233 (Non-precedential)0
In re Huping Hu: Quantum Entanglement, Medical Innovation, and Patentability on the Scientific “Fringe”0
Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Navigating Cross-Border Challenges In Biobanking: Analysing Eu Legislation, ECJ Case Law, and the Role of Private International Law0
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Biotechnology Law Report0
A Feasible Pathway for Open Access to Human Embryonic Stem Cell Patents—With China's Open License for Patent as the Entry Point0
Genentech, Inc. v. Sandoz, Inc.0
Novartis Pharms. Corp. v. Accord Healthcare, Inc.0
Janssen Ortho, LLC v. United States0
Hologic, Inc. v. Minerva Surgical, Inc.0
An Innovation Principle in Gene Technology Law?0
Moo-re Gene-edited Animals Get Regulatory Clearance: U.S. FDA Approves Genetically Engineered Cattle for Human Consumption0
Valeant Pharm. N. Am. LLC v. Mylan Pharm. Inc. United States Court of Appeals of the Federal Circuit, 2020 978 F.3d 13740
Glaxosmithkline LLC v. Teva Pharmaceuticals USA, Inc. United States Court of Appeals of the Federal Circuit, 2020 976 F.3d 13470
Patent Term Adjustment: Recent Developments at the Federal Circuit and PTO0
Branded Drug Companies Are Successfully Asserting the Doctrine of Equivalents in Hatch-Waxman Litigation0
ModernaTx, Inc. v. Arbutus Biopharma Corp.0
Baxalta Inc. v. Genentech, Inc. United States Court of Appeals of the Federal Circuit, 2020972 F.3d 13410
In Minerva v. Hologic, the U.S. Supreme Court Reins in the Equitable Doctrine of Assignor Estoppel0
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.United States Court of Appeals of the Federal Circuit, 20217 F.4th 13200
Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc.0
In re Couvaras0
Willowood v. Syngenta Petition for Certiorari Asks Supreme Court to Weigh in on Copyright Protection for Generic Pesticide Labeling0
Biosafety in Public Health Emergency: China's Path and Global Governance0
Pac. Biosciences of California, Inc. v. Oxford Nanopore Techs., Inc. United States Court of Appeals of the Federal Circuit, 2021 996 F.3d 1340
Biotechnology and Intellectual Property Law: Theoretical and Practical Reflections on Albanian National Law and Jurisprudence in Comparison with EU Acquis and ECJ Case Law0
Government Involvement in Pharmaceutical Development Can Come Back to Haunt a Drug Company0
Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 13680
Selected Developments in Biotechnology Law and the Biotechnology Industry0
H. Lundbeck A/S v. Lupin Ltd.0
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws0
Arbutus Biopharma Corp. v. ModernaTX, Inc. United States Court of Appeals of the Federal Circuit, 2023 65 F.4th 6560
Immunex Corp. v. Sanofi-Aventis U.S. LLC United States Court of Appeals of the Federal Circuit, 202977 F.3d 12120
Selected Developments in Biotechnology Law and the Biotechnology Industry0
C R Bard Inc. v. AngioDynamics, Inc. United States Court of Appeals of the Federal Circuit, 2020 979 F.3d 13720
CJEU Installs Another Hurdle for SPCs on Functionally Defined Products and Ends Second Medical Use SPCs0
Inherency in the Patenting of Biotechnology and Pharmaceutical Innovation0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-190
Regulating Unproven Stem Cell Interventions: How Effective Are the ISSCR Guidelines?0
Minerva Surgical, Inc. v. Hologic, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 13710
Recent Developments in FDA Regulatory Exclusivities0
HIPAA, HIPPA, or HIPPO: What Really Is the Heath Insurance Portability and Accountability Act?0
Recent Developments in the Listing of Patents in FDA's Orange Book0
Interrelationship Between Genetic Resources and Traditional Knowledge: An Example from Earthworm Fibrinolytic Enzyme0
A Pharmaceutical Formulation as a Claim Term Cannot “Target” a Plasma Concentration-Time Profile Under 35 U.S.C. § 112: A Lesson from Horizon Pharma, Inc. v. Dr. Reddy's Laboratories Inc.0
0.043632984161377